Research Funded To Date

DEVELOPMENT OF AN ORAL FORMULATION AND TOXICITY STUDIES FOR INHIBITOR, WP1066, OF THE SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 – A PATHWAY THAT DRIVES THE DEVELOPMENT OF MALIGNANT BRAIN TUMORS AND IMMUNE SUPPRESSION.

PIs: Amy Heimberger, M.D.
Professor, Neurosurgery
MD Anderson Cancer Center

Waldemar Priebe, M.Sc., Ph.D.
Professor, Experimental Therapeutics Department
MD Anderson Cancer Center

Charles A. Conrad, M.D.
Professor, Neuro-Oncology
MD Anderson Cancer Center

Award:  $728,550 over two years


COMBINING A PATIENT’S OPTIMIZED DENDRITIC CELLS (POTENT IMMUNE STIMULATORS) WITH POOLED AND WELL-CHARACTERIZED LYSATES FROM OTHER PATIENTS’ BRAIN TUMOR CULTURES TO GENERATE AN ANTI-TUMOR VACCINE INCORPORATING NEW METHODS FOR MONITORING CHANGES IN THE IMMUNE SYSTEM.

PI: Allan B. Dietz, Ph.D.
Scientific Director, Human Cell Therapy Lab
Mayo Clinic

Award: $1,192,658 over three years


A PHASE O CLINICAL TRIAL OF A NOVEL MOLECULARLY-TARGETED THERAPY FOR RECURRENT GLIOBLASTOMA PATIENTS.

PI:  Nader Sanai, M.D.
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center
Barrow Neurological Institute

Award:  $355,740 over two years


PRECLINICAL EVALUATION OF A PATIENT-SPECIFIC NEOANTIGEN VACCINATION STRATEGY, AN IMPLANTABLE VACCINE DEVICE AND COMBINATORIAL REGIMENS TO ENHANCE ANTI-TUMOR IMMUNE RESPONSES.

PI: David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute

Award: $1,500,000 over three years


DEVELOPING AND CLINICALLY TRANSLATING TECHNOLOGIES AND BIOLOGICAL KNOWLEDGE DESIGNED TO HELP ANTICIPATE AND TREAT THERAPY RESISTANCE IN GBM PATIENTS, PRIOR TO THE APPEARANCE OF THAT RESISTANCE.

PIs: Timothy Cloughesy, M.D.
Director and Professor, Neuro-Oncology Program
University of California Los Angeles (UCLA)

James R. Heath, Ph.D.
Elizabeth W. Gilloon Professor of Chemistry
California Institute of Technology

Paul S. Mischel, M.D.
Member and Head Professor, Laboratory of Molecular Pathology
Ludwig Institute for Cancer Research
University of California San Diego (UCSD)

Award: $1,500,000 over three years


TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, BARROW NEUROLOGICAL INSTITUTE, AND NEUMOCORE, INC. COLLABORATING TO TEST FDA APPROVED DRUGS KNOWN TO PASS THE BLOOD BRAIN BARRIER FOR EFFICACY AND ACCELERATED USE IN GBM PATIENTS.

PI:  Jeffrey M. Trent, Ph.D.
President and Research Director
Translational Genomics Research Institute (TGen)

Award:  $3,700,000 over three years


NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM AT TGEN DESIGNED TO GIVE HIGH SCHOOL AND UNDERGRADUATE STUDENTS INTENSIVE, HANDS-ON RESEARCH EXPERIENCE WORKING ALONGSIDE A MENTOR-SCIENTIST TO LEARN ABOUT TRANSLATIONAL RESEARCH WHILE INVESTIGATING QUESTIONS WITHIN THE NEUROLOGICAL SCIENCES.

PI: Brandy Wells
Director, Public Affairs and Education
Translational Genomics Research Institute (TGen)

Award:  $91,824